Do analysts prefer HURA or MIRA?

TuHURA Biosciences currently has a consensus price target of $9.00, suggesting a potential upside of 326.54%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe TuHURA Biosciences is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TuHURA Biosciences 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, HURA or MIRA?

TuHURA Biosciences is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TuHURA Biosciences N/A N/A -$30.05M -$0.61 N/A MIRA Pharmaceuticals N/A N/A -$10.44M -$1.30 N/A

Is HURA or MIRA more profitable?

MIRA Pharmaceuticals' return on equity of -140.82% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.12% -105.38% MIRA Pharmaceuticals N/A -140.82% -135.01%

Do analysts rate MIRA or CNTB?

Connect Biopharma has a consensus target price of $7.29, suggesting a potential upside of 240.45%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Connect Biopharma is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Connect Biopharma 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75

Is MIRA or CNTB more profitable?

Connect Biopharma's return on equity of -122.29% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets MIRA Pharmaceuticals N/A -140.82% -135.01% Connect Biopharma N/A -122.29% -97.07%

Do analysts prefer ASRT or MIRA?

Assertio presently has a consensus price target of $22.65, indicating a potential downside of 3.62%. Given Assertio's higher possible upside, equities research analysts clearly believe Assertio is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Assertio 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate MIRA or PYXS?

Pyxis Oncology has a consensus price target of $6.86, suggesting a potential upside of 162.73%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Pyxis Oncology 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is MIRA or PYXS more profitable?

Pyxis Oncology's return on equity of -135.60% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets MIRA Pharmaceuticals N/A -140.82% -135.01% Pyxis Oncology N/A -135.60% -85.00%

Do analysts recommend MIRA or NGEN?

NervGen Pharma has a consensus target price of $14.00, suggesting a potential upside of 758.90%. Given NervGen Pharma's stronger consensus rating and higher probable upside, analysts clearly believe NervGen Pharma is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 NervGen Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.83

Which has preferable earnings and valuation, MIRA or NGEN?

NervGen Pharma is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MIRA Pharmaceuticals N/A N/A -$10.44M -$1.30 N/A NervGen Pharma N/A N/A N/A -$0.09 N/A

Is MIRA or NGEN more profitable?

NervGen Pharma's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets MIRA Pharmaceuticals N/A -140.82% -135.01% NervGen Pharma N/A N/A N/A

MIRA Pharmaceuticals (MIRA) Competitors

$0.88 -0.05 (-4.97%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$0.87 -0.01 (-1.22%)

As of 07/24/2026 07:34 PM Eastern

Compare

MIRA vs. HURA, CNTB, ASRT, PYXS, and NGEN

Should you buy MIRA Pharmaceuticals stock or one of its competitors? MarketBeat compares MIRA Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MIRA Pharmaceuticals include TuHURA Biosciences (HURA), Connect Biopharma (CNTB), Assertio (ASRT), Pyxis Oncology (PYXS), and NervGen Pharma (NGEN). These companies are all part of the "pharmaceutical products" industry.

How does MIRA Pharmaceuticals compare to TuHURA Biosciences?

TuHURA Biosciences (NASDAQ:HURA) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

TuHURA Biosciences currently has a consensus price target of $9.00, suggesting a potential upside of 326.54%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe TuHURA Biosciences is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

TuHURA Biosciences has a beta of -0.05, indicating that its share price is 105% less volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

TuHURA Biosciences is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A

MIRA Pharmaceuticals' return on equity of -140.82% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.12%	-105.38%
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%

0.6% of TuHURA Biosciences shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 6.1% of TuHURA Biosciences shares are held by insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, TuHURA Biosciences had 4 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 5 mentions for TuHURA Biosciences and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 1.89 beat TuHURA Biosciences' score of 0.94 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
TuHURA Biosciences	Positive
MIRA Pharmaceuticals	Very Positive

Summary

MIRA Pharmaceuticals beats TuHURA Biosciences on 7 of the 13 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Connect Biopharma?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

MIRA Pharmaceuticals has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.23, indicating that its share price is 123% less volatile than the broader market.

Connect Biopharma has a consensus target price of $7.29, suggesting a potential upside of 240.45%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Connect Biopharma is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Connect Biopharma's return on equity of -122.29% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%
Connect Biopharma	N/A	-122.29%	-97.07%

MIRA Pharmaceuticals has higher earnings, but lower revenue than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A
Connect Biopharma	$233K	578.30	-$55.48M	-$1.15	N/A

35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by company insiders. Comparatively, 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Connect Biopharma had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 2 mentions for Connect Biopharma and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 1.89 beat Connect Biopharma's score of 1.73 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
MIRA Pharmaceuticals	Very Positive
Connect Biopharma	Very Positive

Summary

Connect Biopharma beats MIRA Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Assertio?

Assertio (NASDAQ:ASRT) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

MIRA Pharmaceuticals has lower revenue, but higher earnings than Assertio. Assertio is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A

Assertio has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market.

49.0% of Assertio shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 5.7% of Assertio shares are held by company insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MIRA Pharmaceuticals has a net margin of 0.00% compared to Assertio's net margin of -34.94%. Assertio's return on equity of -38.72% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-34.94%	-38.72%	-13.32%
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%

Assertio presently has a consensus price target of $22.65, indicating a potential downside of 3.62%. Given Assertio's higher possible upside, equities research analysts clearly believe Assertio is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, MIRA Pharmaceuticals had 1 more articles in the media than Assertio. MarketBeat recorded 1 mentions for MIRA Pharmaceuticals and 0 mentions for Assertio. MIRA Pharmaceuticals' average media sentiment score of 1.89 beat Assertio's score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Assertio	Neutral
MIRA Pharmaceuticals	Very Positive

Summary

MIRA Pharmaceuticals beats Assertio on 10 of the 15 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Pyxis Oncology?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Pyxis Oncology has a consensus price target of $6.86, suggesting a potential upside of 162.73%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 6.7% of MIRA Pharmaceuticals shares are owned by insiders. Comparatively, 5.7% of Pyxis Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MIRA Pharmaceuticals has higher earnings, but lower revenue than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A
Pyxis Oncology	$13.86M	11.93	-$79.62M	-$1.31	N/A

Pyxis Oncology's return on equity of -135.60% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%
Pyxis Oncology	N/A	-135.60%	-85.00%

In the previous week, Pyxis Oncology had 3 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 4 mentions for Pyxis Oncology and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 1.89 beat Pyxis Oncology's score of 0.80 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
MIRA Pharmaceuticals	Very Positive
Pyxis Oncology	Positive

MIRA Pharmaceuticals has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market.

Summary

Pyxis Oncology beats MIRA Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to NervGen Pharma?

MIRA Pharmaceuticals (NASDAQ:MIRA) and NervGen Pharma (NASDAQ:NGEN) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

NervGen Pharma has a consensus target price of $14.00, suggesting a potential upside of 758.90%. Given NervGen Pharma's stronger consensus rating and higher probable upside, analysts clearly believe NervGen Pharma is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

In the previous week, NervGen Pharma had 2 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 3 mentions for NervGen Pharma and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 1.89 beat NervGen Pharma's score of 0.62 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
MIRA Pharmaceuticals	Very Positive
NervGen Pharma	Positive

NervGen Pharma's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%
NervGen Pharma	N/A	N/A	N/A

NervGen Pharma is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A
NervGen Pharma	N/A	N/A	N/A	-$0.09	N/A

35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by insiders. Comparatively, 5.8% of NervGen Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

NervGen Pharma beats MIRA Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Get MIRA Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIRA vs. The Competition

Export

Metric	MIRA Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$38.99M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-0.68	21.29	27.11	23.64
Price / Sales	N/A	170.12	517.09	89.57
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	3.53	7.88	10.28	6.07
Net Income	-$10.44M	$23.86M	$3.60B	$331.99M
7 Day Performance	-8.14%	-3.82%	-1.27%	-0.63%
1 Month Performance	-2.85%	-2.61%	-0.37%	-2.00%
1 Year Performance	-49.03%	32.79%	18.30%	13.62%

MIRA Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIRA MIRA Pharmaceuticals	0.6927 of 5 stars	$0.88 -5.0%	N/A	-49.3%	$38.99M	N/A	N/A	2	Positive News Gap Up
HURA TuHURA Biosciences	2.1755 of 5 stars	$2.41 +1.1%	$9.00 +274.2%	-25.7%	$153.79M	N/A	N/A	N/A	News Coverage
CNTB Connect Biopharma	4.571 of 5 stars	$2.43 +7.5%	$7.29 +199.8%	-8.9%	$152.68M	$60K	N/A	110	News Coverage High Trading Volume
ASRT Assertio	1.7184 of 5 stars	$23.50 flat	$22.65 -3.6%	N/A	$151.81M	$118.71M	N/A	20	Upcoming Earnings
PYXS Pyxis Oncology	2.9929 of 5 stars	$2.34 -4.3%	$6.86 +193.7%	+94.8%	$149.00M	$13.86M	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIRA) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MIRA Pharmaceuticals (MIRA) Competitors

MIRA vs. HURA, CNTB, ASRT, PYXS, and NGEN

How does MIRA Pharmaceuticals compare to TuHURA Biosciences?

Summary

How does MIRA Pharmaceuticals compare to Connect Biopharma?

Summary

How does MIRA Pharmaceuticals compare to Assertio?

Summary

How does MIRA Pharmaceuticals compare to Pyxis Oncology?

Summary

How does MIRA Pharmaceuticals compare to NervGen Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA vs. The Competition

MIRA Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MIRA Pharmaceuticals (MIRA) Competitors

MIRA vs. HURA, CNTB, ASRT, PYXS, and NGEN

How does MIRA Pharmaceuticals compare to TuHURA Biosciences?

Do analysts prefer HURA or MIRA?

Which has more risk and volatility, HURA or MIRA?

Which has higher earnings & valuation, HURA or MIRA?

Is HURA or MIRA more profitable?

Do institutionals & insiders have more ownership in HURA or MIRA?

Does the media prefer HURA or MIRA?

Summary

How does MIRA Pharmaceuticals compare to Connect Biopharma?

Which has more risk & volatility, MIRA or CNTB?

Do analysts rate MIRA or CNTB?

Is MIRA or CNTB more profitable?

Which has better earnings & valuation, MIRA or CNTB?

Do institutionals and insiders believe in MIRA or CNTB?

Does the media favor MIRA or CNTB?

Summary

How does MIRA Pharmaceuticals compare to Assertio?

Which has stronger earnings & valuation, ASRT or MIRA?

Which has more volatility and risk, ASRT or MIRA?

Do institutionals & insiders have more ownership in ASRT or MIRA?

Is ASRT or MIRA more profitable?

Do analysts prefer ASRT or MIRA?

Does the media favor ASRT or MIRA?

Summary

How does MIRA Pharmaceuticals compare to Pyxis Oncology?

Do analysts rate MIRA or PYXS?

Do institutionals and insiders hold more shares of MIRA or PYXS?

Which has stronger earnings and valuation, MIRA or PYXS?

Is MIRA or PYXS more profitable?

Does the media prefer MIRA or PYXS?

Which has more risk & volatility, MIRA or PYXS?

Summary

How does MIRA Pharmaceuticals compare to NervGen Pharma?

Do analysts recommend MIRA or NGEN?

Does the media refer more to MIRA or NGEN?

Is MIRA or NGEN more profitable?

Which has preferable earnings and valuation, MIRA or NGEN?

Do insiders & institutionals hold more shares of MIRA or NGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA vs. The Competition

MIRA Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools